Literature DB >> 31800422

Long-Term Outcomes of Pectoralis Major Transfer for the Treatment of Irreparable Subscapularis Tears: Results After a Mean Follow-up of 20 Years.

Lukas Ernstbrunner1, Karl Wieser1, Sabrina Catanzaro1, Christoph A Agten1, Paolo Fornaciari1, David E Bauer1, Christian Gerber1.   

Abstract

BACKGROUND: One recognized salvage option in the treatment of an irreparable subscapularis tear is the pectoralis major tendon transfer (PMT). We aimed to analyze the long-term clinical and imaging outcome of PMT for irreparable subscapularis deficiency.
METHODS: Twenty-eight consecutive patients representing 30 shoulders underwent PMT at a mean age of 53.0 years (range, 35 to 67 years). At a mean of 19.7 years (range, 18 to 22 years) postoperatively, 24 shoulders (80%) were clinically examined and 21 were radiographically and sonographically assessed. The long-term results were compared with preoperative findings and previously published short-term results.
RESULTS: The mean relative Constant score (percentage of age and sex-matched normal scores; CS%) and the Subjective Shoulder Value (SSV) both improved significantly from preoperatively (CS%, 47%, and SSV, 22%) to postoperatively (CS%, 77%, and SSV, 71%; p < 0.001 for both). All patients rated their results as good or excellent. Active anterior elevation was improved from preoperatively (120°) to postoperatively (131°), but the difference was not significant. Active internal and external rotation decreased significantly from the short-term (32-month) follow-up to the time of the latest follow-up (p = 0.005 and p = 0.002, respectively); however, internal rotation remained at 6 points compared with the 8 points recorded at short-term follow-up and external rotation decreased only from a mean of 51° to 39°. Loss of active range of motion was not observed subjectively and was not subjectively limiting, represented by the high ultimate SSV and overall satisfaction. Four shoulders (19%) showed evidence of glenohumeral arthropathy (Samilson and Prieto grade 3), but clinically were mildly symptomatic to asymptomatic at the time of the latest follow-up (CS% range, 67% to 88%; SSV range, 70% to 80%). Rupture of the PMT was sonographically identified in 2 patients (10%) and was associated with radiographic evidence of advanced cuff tear arthropathy (Hamada stages ≥4). Six (20%) of the initial 30 shoulders were revised, and 1 (4%) of the 24 shoulders that were clinically examined underwent reverse total shoulder arthroplasty.
CONCLUSIONS: At long-term follow-up, PMT for isolated and combined subscapularis tears is associated with good to excellent clinical results. Although one-third of the shoulders developed mildly symptomatic or asymptomatic osteoarthritis, the need for salvage with use of reverse total shoulder arthroplasty was rare. LEVEL OF EVIDENCE: Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2019        PMID: 31800422     DOI: 10.2106/JBJS.19.00172

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  4 in total

1.  Tendon transfers for irreparable rotator cuff tears.

Authors:  John R Adam; Shashi K T Nanjayan; Melissa Johnson; Amar Rangan
Journal:  J Clin Orthop Trauma       Date:  2021-04-03

Review 2.  Pectoralis major and pectoralis minor transfer for irreparable subscapularis tendon tears.

Authors:  José Fernando Sánchez Carbonel; Maximilian Hinz; Christian Lozano; Benjamin Daniel Kleim; Andreas B Imhoff; Sebastian Siebenlist
Journal:  Oper Orthop Traumatol       Date:  2022-02-03       Impact factor: 1.154

3.  Anatomical study of the teres major muscle: description of an additional distal muscle slip.

Authors:  Lukas Ernstbrunner; Malik Jessen; Marco Rohner; Manuel Dreu; Samy Bouaicha; Karl Wieser; Paul Borbas
Journal:  BMC Musculoskelet Disord       Date:  2021-04-16       Impact factor: 2.362

Review 4.  Tendon transfers for massive rotator cuff tears.

Authors:  Antonio Cartucho
Journal:  EFORT Open Rev       Date:  2022-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.